A randomised, double-blind, placebo-controlled, parallel group trial evaluating safety, tolerability, pharmacodynamics and pharmacokinetics of BI 1291583 one tablet once daily over 12 weeks versus placebo in adult patients with cystic fibrosis bronchiectasis (ClairaflyTM)


Status: Ongoing


This study is being done to test the study drug, BI 1291583, for safety and side effects, when compared to a placebo, in subjects who have cystic fibrosis with bronchiectasis (CFB).

Sponsor: Sponsor: Boehringer Ingelheim Pharmaceuticals, Inc.

NCT05865886 - IRB# 2023-162